Navigation Links
Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments

Individuals with moderate to severe chest pains (angina) who have not found relief from medication may benefit from a new gene therapy approach being used by cardiologists at Rush University Medical Center to grow new blood vessels in the heart.

The phase II clinical research study uses vascular endothelial growth factor-2 (VEGF-2) in the form of a solution containing a DNA plasmid that is delivered using catheterization to heart tissue that has been damaged from insufficient blood flow.

Once the catheter reaches the targeted site inside of the heart, the VEGF-2 is injected into the heart muscle region with inadequate blood supply. The DNA plasmid is then taken up by the middle muscular layer of the heart wall near the injection site. Inside the cell, the DNA encoded VEGF-2 expresses itself which in turn stimulates the growth of new blood vessels by promoting the proliferation of endothelial cells in the heart.

New blood vessels are required to provide oxygen-carrying blood to heart muscles to compensate for the blocked heart arteries. The subsequent, improved blood flow relieves the painful symptoms of angina.

"The process of growing new blood vessels, or angiogenesis, should occur over the course of four to eight weeks following the procedure which is done in the cardiac catheterization lab at Rush," said Dr. Gary L. Schaer, the principal investigator of the trial at Rush and director of the Rush Cardiac Catheterization Labs. "The patient goes home the next day." Several patients have received the gene therapy and all are doing well.

Individuals who may be candidates for this gene therapy study trial must have moderate to severe angina, but cannot also be candidates for treatment using angioplasty or bypass surgery. Angioplasty involves a catheterization with a balloon-like device that opens blocked arteries, while bypass surgery requires open-heart surgery to place veins removed from the patient's leg or arteries taken from the patient's chest wall or arm to "bypass" the blocked blood vessels.

While both of these treatments have been shown to be successful in relieving severe chest pains resulting from blocked arteries, a significant percentage of patients eventually do not respond well to either treatment, often requiring another angioplasty or bypass operation, noted Schaer. "If gene therapy proves to be safe and effective, it will represent an important new approach to improve the quality of life in these seriously ill patients with refractory chest pain," said Dr. R. Jeffrey Snell, study co-investigator and Schaer's colleague at Rush.

In the new study, patients will be randomly assigned to receive the gene administered through a cardiac catheter threaded into the heart from a leg artery or a placebo delivered using the same method. As required by the U.S. Food and Drug Administration, the study is "double blinded," which means that neither the doctor nor the patient will know whether he or she is receiving the gene therapy or a placebo. For every three patients that receive the active gene, one will receive a placebo. Following treatment, patients enrolled in the study will be examined for chest pain at one month, three months and six months. A total of 404 patients will be enrolled in the study at the 20 study sites across the country.

The Genetic Angiogenic Stimulation Investigational Study (GENASIS) is funded by Corautus Genetics.

More than 11 million people in the United States suffer from coronary artery disease. Many patients receive medications to increase blood flow but nearly 500,000 angioplasties and coronary bypass procedures are performed each year in those patients who do not benefit from medication.


Source:Rush University Medical Center

Related biology news :

1. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
2. Researchers Closer To Helping Hearing-Impaired Using Stem Cells
3. Using nanoparticles, in vivo gene therapy activates brain stem cells
4. Using computers and DNA to count bacteria
5. Using the genomic shortcut to predict bacterial behavior
6. Using natures most primitive anti-viral defense system to find new approaches to cancer research
7. Using dental X-rays to detect osteoporosis
8. Using brain scans, researchers find evidence for a two-stage model of human perceptual learning
9. Using nanomagnets to enhance medical imaging
10. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
11. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
Post Your Comments:

(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
(Date:10/23/2015)... 23, 2015 Research and Markets ( ... Voice Recognition Biometrics Market 2015-2019" report to their ... The global voice recognition biometrics market to grow ... --> --> The report, ... based on an in-depth market analysis with inputs from ...
Breaking Biology News(10 mins):
(Date:11/28/2015)... ... , ... • Jeon Jin Bio Corp, a Korean Biotech venture company, has ... , Bird Free, an oil-based, gel formula made from ... visual, smell, taste and touch, enabling safe, effective avian control without toxic chemicals , ...
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to ... presentations offered in symposia, oral sessions, workshops, awards, and posters. The core ... of applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, ...
(Date:11/26/2015)... 2015 ... Research Laboratories, a leading independent and ... has formed a strategic partnership with ... Health for joint work on clinical ... ) , --> ,     ...
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
Breaking Biology Technology: